Shire

ShireShire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

www.shire.com

Shire RSS Channel

Display # 
Title Published Date
One family's history of the rare condition Fabry disease through the generations 28 April 2016
Shire to combine with Baxalta, creating the global leader in rare diseases 14 January 2016
Shire partners with CrowdMed to offer US employees an innovative digital crowdsourcing diagnostic service 09 December 2015
Shire acquires Meritage Pharma 24 February 2015
Shire acquires Premacure AB 12 March 2013
Shire and Boston Children's Hospital enter into broad research collaboration 20 November 2012
Shire continued strong product sales performance in Q3 28 October 2011
Shire to establish new Regenerative Medicine business unit through cash acquisition of Advanced BioHealing, Inc. 18 May 2011
Shire delivers a strong first quarter performance 28 April 2011
Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse® 10 January 2011
Shire Expands Pipeline to Treat Orphan Muscle Diseases through Collaboration with Acceleron Pharma 10 September 2010
Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships 01 September 2010
Shire Proposes to Expand Specialist Gastrointestinal Portfolio 04 August 2010
Shire Purchases Strategic Site in Massachusetts 01 July 2010
VYVANSE® - new ADHD treatment option - now available in Canada 02 February 2010
FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity 26 October 2009
Shire Limited has changed its name to Shire plc 01 October 2008
Shire proposes acquisition of Jerini AG for an equity purchase price of €328 million 04 July 2008
Shire plc accelerating new product sales drive revenue growth of 36% 21 February 2008
Shire's ELAPRASE® (idursulfase) Approved in Japan For the Treatment of Hunter Syndrome 05 October 2007

Most Popular Now

AstraZeneca and Eli Lilly and Compa…

AstraZeneca and Eli Lilly and Company today announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in...

Read more

NIH launches large clinical trials …

Enrollment has begun in the first of two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection. Known as the A...

Read more

Pfizer announces termination of pro…

Pfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The deci...

Read more

New analysis shows only minority of…

Boehringer Ingelheim has announced a new publication showing that levels of white blood cells called eosinophils can help identify patients with COPD who may and may not ...

Read more

Researchers open the way to new tre…

In a recent paper published in Nature Communications, a group of Case Western University School of Medicine researchers presented their discovery of the full-length struc...

Read more

Implantable device targets pancreat…

Pancreatic cancer is the third leading cause of cancer deaths in the United States, in part because it is very difficult for chemotherapy drugs to reach the pancreas, whi...

Read more

Physicians' knowledge about FDA app…

Since 2012, the FDA can designate a drug as a "breakthrough therapy" if preliminary clinical evidence - such as an improvement in a pharmacodynamic biomarker - suggests a...

Read more

FDA grants priority review for Roch…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) and granted P...

Read more

Global spending on health is expect…

Global inequities in health spending are expected to persist and intensify over the next 25 years, according to a new study that estimates total health financing in count...

Read more

Americans live longer but with disa…

Americans are living longer but in poorer health, according to a new study. The USC-led study examined life expectancy trends and disability rates in a 40-year period, fr...

Read more

Nanoparticles show promise for trea…

Nanoparticles designed to block a cell-surface molecule that plays a key role in inflammation could be a safe treatment for inflammatory bowel disease (IBD), according to...

Read more

Johnson & Johnson announces lau…

Johnson & Johnson today announced the official launch of its global public health strategy at the opening of its companies' on-the-ground global public health operations ...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]